The fumaric acid ester BG-12: a new option in MS therapy

References

• Schweckendieck W. Treatment of psoriasis vulgaris. Med. Monatsschr. 13, 103–104 (1959).
   PubMedGoogle Scholar
• Nast A, Boehncke WH, Mrowietz U et al.; Deutsche Dermatologische Gesellschaft; Berufsverband Deutscher Dermatologen. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch. Dermatol. Res. 304(2), 87–113 (2012).
   PubMed Web of Science ®Google Scholar
• Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis–a retrospective study (FUTURE). J. Dtsch. Dermatol. Ges. 7(7), 603–611 (2009).
   PubMed Web of Science ®Google Scholar
• Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int. J. Clin. Pract. 61(11), 1922–1930 (2007).
   PubMed Web of Science ®Google Scholar
• Lassaigne. Ann. Chim. Phys. 11, 93 (1819).
   Google Scholar
• Litjens NH, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol. 58(4), 429–432 (2004).
   PubMed Web of Science ®Google Scholar
• Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch. Dermatol. Res. 302(7), 531–538 (2010).
   PubMedGoogle Scholar
• Litjens NH, van Strijen E, van Gulpen C et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 4, 22 (2004).
   PubMedGoogle Scholar
• Nibbering PH, Thio B, Zomerdijk TP, Bezemer AC, Beijersbergen RL, van Furth R. Effects of monomethylfumarate on human granulocytes. J. Invest. Dermatol. 101(1), 37–42 (1993).
   PubMed Web of Science ®Google Scholar
• Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm. Drug Dispos. 24(6), 259–273 (2003).
   PubMed Web of Science ®Google Scholar
• Itoh K, Wakabayashi N, Katoh Y et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13(1), 76–86 (1999).
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamoto SI, Cui J et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc. Natl. Acad. Sci. U.S.A. 103(3), 768–773 (2006).
   PubMed Web of Science ®Google Scholar
• Satoh T, Harada N, Hosoya T, Tohyama K, Yamamoto M, Itoh K. Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice. Biochem. Biophys. Res. Commun. 380(2), 298–302 (2009).
   PubMedGoogle Scholar
• Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35(3), 238–245 (2003).
   PubMed Web of Science ®Google Scholar
• Chen PC, Vargas MR, Pani AK et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A. 106(8), 2933–2938 (2009).
   PubMed Web of Science ®Google Scholar
• Duffy S, So A, Murphy TH. Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J. Neurochem. 71(1), 69–77 (1998).
   PubMed Web of Science ®Google Scholar
• Ellrichmann G, Petrasch-Parwez E, Lee DH et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington’s disease. PLoS ONE 6(1), e16172 (2011).
   PubMed Web of Science ®Google Scholar
• Hubbs AF, Benkovic SA, Miller DB et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am. J. Pathol. 170(6), 2068–2076 (2007).
   PubMed Web of Science ®Google Scholar
• Khodagholi F, Eftekharzadeh B, Maghsoudi N, Rezaei PF. Chitosan prevents oxidative stress-induced amyloid beta formation and cytotoxicity in NT2 neurons: involvement of transcription factors Nrf2 and NF-kappaB. Mol. Cell. Biochem. 337(1-2), 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Kim YS, Podder B, Song HY. Cytoprotective effect of alpha-lipoic acid on paraquat-exposed human bronchial epithelial cells via activation of nuclear factor erythroid related factor-2 pathway. Biol. Pharm. Bull. 36(5), 802–811 (2013).
   PubMed Web of Science ®Google Scholar
• Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 24(5), 1101–1112 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 278(14), 12029–12038 (2003).
   PubMed Web of Science ®Google Scholar
• Lewerenz J, Albrecht P, Tien ML et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111(2), 332–343 (2009).
   PubMed Web of Science ®Google Scholar
• Liu Y, Kern JT, Walker JR, Johnson JA, Schultz PG, Luesch H. A genomic screen for activators of the antioxidant response element. Proc. Natl. Acad. Sci. USA. 104(12), 5205–5210 (2007).
   PubMed Web of Science ®Google Scholar
• Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 21(3), 705–710 (2008).
   PubMed Web of Science ®Google Scholar
• Sasaki S, Tozawa T, Sugamoto K, Matsushita YI, Satoh T. A novel di terpene para-hydroquinone compound derived from cryptoquinone protects neuronal cells against oxidative stress and activates the Nrf2/ARE pathway. Neurosci. Lett. (2013).
   Google Scholar
• Scannevin RH, Chollate S, Jung MY et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 341(1), 274–284 (2012).
   PubMed Web of Science ®Google Scholar
• Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145(1), 101–107 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart D, Killeen E, Naquin R, Alam S, Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 278(4), 2396–2402 (2003).
   PubMed Web of Science ®Google Scholar
• Su JY, Duffy S, Murphy TH. Reduction of H2O2-evoked, intracellular calcium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer. Neurosci. Lett. 273(2), 109–112 (1999).
   PubMedGoogle Scholar
• Tabrizi SJ, Workman J, Hart PE et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47(1), 80–86 (2000).
   PubMed Web of Science ®Google Scholar
• Thiessen A, Schmidt MM, Dringen R. Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1. Neurosci. Lett. 475(1), 56–60 (2010).
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Thomas B et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS ONE 4(6), e5757 (2009).
   PubMed Web of Science ®Google Scholar
• Yu M, Xu M, Liu Y et al. Nrf2/ARE is the potential pathway to protect Sprague-Dawley rats against oxidative stress induced by quinocetone. Regul. Toxicol. Pharmacol. 66(3), 279–285 (2013).
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678–692 (2011).
   PubMed Web of Science ®Google Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26(9), 2067–2074 (1996).
   PubMed Web of Science ®Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol. 139(3), 390–395 (1998).
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 234(1), 19–23 (1997).
   PubMed Web of Science ®Google Scholar
• Rubant SA, Ludwig RJ, Diehl S et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J. Invest. Dermatol. 128(2), 326–331 (2008).
   PubMed Web of Science ®Google Scholar
• Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br. J. Dermatol. 156(5), 838–842 (2007).
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 11(1), 43–48 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116(2), 203–208 (2001).
   PubMed Web of Science ®Google Scholar
• Loewe R, Holnthoner W, Gröger M et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 168(9), 4781–4787 (2002).
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 7, 30 (2010).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Brück J, Kellerer C et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208(11), 2291–2303 (2011).
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251(3), 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA. The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol. Sci. 114(2), 237–246 (2010).
   PubMedGoogle Scholar
• Berer K, Mues M, Koutrolos M et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479(7374), 538–541 (2011).
   PubMed Web of Science ®Google Scholar
• Esplugues E, Huber S, Gagliani N et al. Control of TH17 cells occurs in the small intestine. Nature 475(7357), 514–518 (2011).
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Manzel A, Titze J et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496(7446), 518–522 (2013).
   PubMed Web of Science ®Google Scholar
• Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13(6), 604–610 (2006).
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH et al.; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648), 1463–1472 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing–remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult. Scler. 18(3), 314–321 (2012).
   PubMedGoogle Scholar
• MacManus DG, Miller DH, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 258(3), 449–456 (2011).
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL et al.; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367(12), 1098–1107 (2012).
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT et al.; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367(12), 1087–1097 (2012).
   PubMed Web of Science ®Google Scholar
• Hanson J, Gille A, Offermanns S. Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol. Ther. 136(1), 1–7 (2012).
   PubMed Web of Science ®Google Scholar
• Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368(17), 1657–1658 (2013).
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Dawson KT, Bozic C. Manufacturer’s response to case reports of PML. N. Engl. J. Med. 368(17), 1659–1661 (2013).
   PubMed Web of Science ®Google Scholar